Antimicrobials

Use of chlorhexidine for the prophylaxis of nosocomial infections in ICU

This review summarizes published data on the use of chlorhexidine for the prevention of nosocomial infections in the intensive care units (ICU). The use of a 0.5–2.0% alcohol solution of chlorhexidine is strongly recommended for the surgical site …

Doxycycline in the current clinical practice

This paper reviews clinical and pharmacological characteristics of doxycycline which is currently indicated for the treatment of some common sexually transmitted infections, pelvic inflammatory diseases, lower respiratory tract infections, several …

To stop the progress of antimicrobial resistance today means to give a chance of mankind surviving tomorrow

Antimicrobial resistance is a global challenge for human society. Scientists around the world are trying not to return to the time when antimicrobials were not yet discovered, and millions of people were dying from infections. This article describes …

Review of the international consensus guidelines for the optimal use of the polymyxins

Polymyxins are often the only agents that remain in vitro active against extensively resistant bacterial pathogens. However, the use of polymyxins is compromised by the number of unresolved issues, including the technical aspects of antimicrobial …

Oral third-generation cephalosporins in the treatment of community-acquired urinary tract infections

Cephalosporins are one of the most commonly used antimicrobials for the treatment of variety of bacterial infections. Prudent use of the third-generation cephalosporins is important for the control of spread of cephalosporin-resistant Gram-negative …

Potential for the use of macrolides in the antimicrobial therapy of severe community-acquired pneumonia in adults

This paper presents mechanism of action and antimicrobial spectrum of macrolides as well as the known acquired resistance mechanisms in the common pathogens causing community-acquired pneumonia, such as Streptococcus pneumoniae and Mycoplasma …

Cefotaxime/sulbactam: clinical and pharmacological characteristics

The recently approved cefotaxime/sulbactam, combination of third-generation cephalosporin (cefotaxime) and beta-lactamase inhibitor (sulbactam), can combat resistance mechanisms associated with the production of serine beta-lactamases, including some …

The evidence base and practical approaches to probiotic use in clinical practice: a focus on Lactobacillus rhamnosus GG and Bifidobacterium lactis Вb-12

Over the last 20 years, there is an ever-increasing interest in the use of probiotics for the variety of health problems worldwide. However, the evidence base for various probiotic microorganisms differs significantly. This review provides data on …

New probiotic strain Streptococcus salivarius K12 in clinical practice

Over the last decades, probiotic strains for topical administration (including oral cavity) have appeared in clinical practice. Streptococcus salivarius K12 is a promising probiotic for prevention and treatment of the upper respiratory tract and ENT …

Ceftolozane/tazobactam – the «new player» in a battle against multiresistant pathogens

Ceftolozane/tazobactam is a new combined antibacterial agent for the treatment of infections caused by gram-negative microorganisms, P. aeruginosa in particular, including strains resistant to other clinically available antimicrobials. In this paper …